Medical
-
Biomarck Pharmaceuticals said that a Phase 2a clinical trial of its BIO-11006 inhalation solution in patients with acute respiratory distress syndrome (ARDS) met its primary endpoint, with a 43% decrease in mortality at 28 days… Read more . . .
-
Theravance Biopharma said that a Phase 1 study of its TD-0903 nebulized JAK inhibitor is now underway. Earlier this month, Theravance announced that it intended to begin clinical development of TD-0903 for the prevention of… Read more . . .
-
The University of Waterloo has announced that School of Pharmacy faculty members Roderick Slavcev and Emmanuel Ho are collaborating with Chemical Engineering professor Marc Aucoin on development of an intranasal vaccine against COVID-19. According to… Read more . . .
-
US-based Enterin Inc. announced that it has been in talks with the FDA in preparation for a Phase 1/2a study of a nebulized formulation of its COV-ENT-1 in patients hospitalized with COVID-19. The company said that… Read more . . .
-
According to Beyond Air, the company has received permission from the FDA to initiate a clinical study of its LungFit inhaled nitric oxide system for the treatment of COVID-19 patients. The announcement comes almost a month… Read more . . .
-
TFF Pharmaceuticals said that it has entered into a 3-year Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for development of dry powder vaccines against alphaviruses such as… Read more . . .
-
Bausch Health announced that Health Canada has approved a clinical trial of the company’s Virazole ribavirin inhalation solution for the treatment of respiratory distress in patients hospitalized with COVID-19, and the study is expected to… Read more . . .
-
Biohaven Pharmaceutical said that the FDA has approved the company’s IND for a Phase 2 study of its vazegepant intranasal calcitonin gene-related peptide (CGRP) receptor antagonist for the reduction of excessive immune response leading to… Read more . . .
-
Theravance Biopharma said that it has submitted a clinical trial application (CTA) to begin clinical development of its TD-0903 nebulized JAK inhibitor for prevention of cytokine storm, which can lead to acute respiratory distress syndrome… Read more . . .
-
TFF Pharmaceuticals has announced a research collaboration deal with the University of Georgia’s Center for Vaccines and Immunology (CVI) and with the University of Texas at Austin (UT Austin) for testing of dry powder universal influenza vaccines formulated using TFF’s… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland